Medically reviewed by Dr. Jyoti Rao, Consultant, Medical Affairs | Published June 2026 | Last reviewed June 2026
Key Takeaways
- The value of disease-modifying therapy in ATTR-CM depends on sustained treatment exposure over time, not one-time prescribing.
- Adherence problems often reflect fragmented care, access barriers, and delayed perceived benefit rather than simple noncompliance.
- Support works best when refill continuity, affordability, and follow-up are integrated into routine clinical care.
- Interrupted treatment persistence can make biomarker and imaging trends much harder to interpret.
Why Treatment Persistence Is an Important Clinical Consideration
In ATTR-CM, adherence and persistence are not secondary operational concerns. They determine whether a disease-modifying strategy is actually delivered in a form that can influence a chronic, progressive cardiomyopathy, so the clinical value of therapy depends not only on selecting treatment but on sustaining exposure long enough for the plan to achieve its intended therapeutic effect. That’s why persistence is a key component of long-term tafamidis therapy.
What Actually Undermines Persistence
Treatment persistence may be compromised by multiple factors, including access barriers, refill disruption, regimen burden, tolerability concerns, multimorbidity, travel demands, and delayed perceived benefit. In that setting, a lapse may reflect limitations within the healthcare delivery pathway as much as patient behavior. Identifying the underlying cause is important, as interventions differ depending on whether the barrier relates to treatment access or tolerability.
How Interrupted Exposure Changes Interpretation
Treatment continuity also influences interpretation of clinical response. Serial natriuretic peptides, functional measures, and imaging are far easier to read when exposure has been stable, whereas an interruption makes it difficult to determine whether a worsening trend means the disease is progressing despite treatment or simply whether treatment exposure was insufficient. A biomarker trend during a refill gap may reflect interrupted treatment as well as underlying disease progression.
Where Adherence Support Is Most Actionable
Adherence support is most effective when systematically integrated into the care pathway rather than provided as non-specific patient counseling: medication reconciliation, affordability review, refill coordination, and repeated reinforcement of why ongoing treatment matters. This is best achieved through multidisciplinary care and structured follow-up.
Clinical Decision Point
Before reading clinical decline as progression despite treatment, confirm that treatment has been continuous. If refill gaps, access interruptions, or treatment interruptions due to tolerability are present, the priority is re-establishing treatment continuity and then reassessing because biomarker and imaging trends are only interpretable against stable exposure. Treatment persistence should be regarded as an integral component of clinical assessment, not merely an administrative follow-up task.
Frequently Asked Questions
Why is treatment persistence clinically important in ATTR-CM?
Disease-modifying therapy only becomes clinically meaningful if exposure is sustained long enough to influence a chronic, progressive disease course.
What usually drives adherence problems in practice?
Access barriers, refill disruption, regimen burden, tolerability concerns, travel demands, and fragmented care often matter as much as individual patient preference.
How do treatment interruptions affect the interpretation of clinical response?
Unstable exposure makes it hard to tell whether the disease is progressing despite treatment or whether the intended treatment exposure has been insufficient to adequately assess response.
What makes adherence support most effective?
Integrating adherence support into routine clinical care—medication reconciliation, affordability review, refill coordination, and reinforcing why treatment continues—rather than relying on generic counseling.
Part of the Spotlight On ATTR-CM resource center.
References:
- Baseline characteristics and secondary medication adherence among Medicare patients diagnosed with ATTR-CM and/or receiving tafamidis prescriptions. PubMed
- Best Practices in Specialized Amyloidosis Centers in the United States. PubMed
- World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). PubMed
- Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy. PubMed
This content is intended for healthcare professionals for educational purposes and is not a substitute for individual clinical judgment. It was developed with AI assistance and reviewed by a qualified healthcare professional for clinical accuracy prior to publication.